Nothing is lower than 0, and 3 is closer to 0 than to 5 - Medicine is not arithmetic

European Heart Journal

Volumn 23, Issue 11, 2002, Pages 840-842

  Colombo, A ^a   Stankovic, G ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE MB;

CARDIOLOGY; CORONARY STENT; EDITORIAL; HUMAN; INTERVENTIONAL RADIOLOGY; MEDICAL LITERATURE; PRIORITY JOURNAL; PUBLICATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

CREATINE KINASE; CREATINE KINASE, MB FORM; HUMANS; ISOENZYMES; MYOCARDIAL INFARCTION; MYOCARDIUM; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS; STENTS;

EID: 0036296214     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.3148     Document Type: Editorial

References (17)

1. Troponisms, necrosettes, enzyme leaks, creatinine phosphokinase bumps, and infarctlets: What's behind this new lexicon and what does it add?
2. Frequency and long-term impact of myonecrosis after coronary stenting
3. Creatine kinase release after successful percutaneous transluminal coronary angioplasty
4. Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-Q wave myocardial infarction associated with coronary angioplasty
5. Influence of postprocedural myocardial infarction on late clinical outcome in the Stent Anti-Thrombotic Regimen Study (STARS)
6. Clinical significance of perioperative Q-wave myocardial infarction: The Emory Angioplasty versus Surgery Trial
7. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation
8. Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions
9. The myth of the myocardial 'infarctlet' during percutaneous coronary revascularization procedures
10. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions
11. Myonecrosis after revascularization procedures
12. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II
13. Minimal myocardial damage during coronary intervention is associated with impaired outcome
14. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting
15. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting
16. Long-term clinical events following creatine kinase-myocardial band isoenzyme elevation after successful coronary stenting
17. Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: A device-specific analysis of 7147 patients